ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 10.66 USD 0.66% Market Closed
Market Cap: 1.1B USD

Wall Street
Price Targets

SPRY Price Targets Summary
ARS Pharmaceuticals Inc

Wall Street analysts forecast SPRY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRY is 28.39 USD with a low forecast of 12.12 USD and a high forecast of 36.75 USD.

Lowest
Price Target
12.12 USD
14% Upside
Average
Price Target
28.39 USD
166% Upside
Highest
Price Target
36.75 USD
245% Upside
ARS Pharmaceuticals Inc Competitors:
Price Targets
ARGX
argenx SE
16% Upside
UTHR
United Therapeutics Corp
4% Upside
MRNA
Moderna Inc
27% Upside
688105
Nanjing Vazyme Biotech Co Ltd
45% Upside
AGIO
Agios Pharmaceuticals Inc
26% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
35% Upside
ACLX
Arcellx Inc
72% Upside
MRUS
Merus NV
3% Upside

Revenue
Forecast

Revenue Estimate
ARS Pharmaceuticals Inc

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 4 years is 53%.

N/A
Past Growth
53%
Estimated Growth
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
ARS Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
ARS Pharmaceuticals Inc

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 4 years is 49%.

N/A
Past Growth
49%
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SPRY's stock price target?
Price Target
28.39 USD

According to Wall Street analysts, the average 1-year price target for SPRY is 28.39 USD with a low forecast of 12.12 USD and a high forecast of 36.75 USD.

What is ARS Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
53%

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 4 years is 53%.

What is ARS Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
49%

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 4 years is 49%.

Back to Top